AZN AstraZeneca PLC
Company Analysis
Latest News
🟢 AstraZeneca is trading 3% up after FDA approval of Ultomiris for IgA nephropathy
AstraZeneca is trading 3.00% up at $173.51 after the FDA granted accelerated U.S. approval for Ultomiris to reduce proteinuria in adults with primary IgA...
🟢 AstraZeneca is trading 3% up today amid Oracle AI clinical-trial collaboration news
AstraZeneca is trading 3.01% higher at $168.88 on October 20, 2026, amid a healthcare rally and its Oracle collaboration announcement. - The non-binding...
AstraZeneca's Efzimfotase Alfa Misses Primary Endpoint in Phase III HICKORY Trial
AstraZeneca's investigational enzyme replacement therapy, efzimfotase alfa, did not meet its primary endpoint in the Phase III HICKORY trial. The trial...
AstraZeneca Bets $1.5 Billion on AI Drug Discovery With insitro — But Can Algorithms Move the Revenue Needle for a $250 Billion Pharma Giant?
Shares of AstraZeneca surged 4.4% to $169.17 Wednesday after the company unveiled a collaboration with AI biotech insitro that could be worth up to $1.5...
🟢 AstraZeneca is trading 4.4% up today after AI drug-discovery collaboration with insitro
AstraZeneca is trading 4.41% up at $169.17, with its AI drug-discovery collaboration with insitro the clearest company-specific catalyst. - The collaboration...
🟢 AstraZeneca is trading 3.14% up in pre-market after announcing a major AI-driven drug discovery collaboration
AstraZeneca is trading at $167.11, up 3.14% in pre-market after announcing a strategic collaboration with AI-focused biotech company insitro. - The...
🟢 AstraZeneca is trading 3.08% up today as healthcare stocks advance
AstraZeneca is trading up 3.08% at $160.62 on October 14 as healthcare stocks advance, with the sector up 1.64%. - UnitedHealth’s earnings beat and raised...
European Markets Open Higher, Led by Tech and Pharmaceutical Sectors
European stock markets started the day on a positive note, with major indexes posting gains at the opening bell. The pan-European STOXX 600 rose, driven by...
AstraZeneca, HUTCHMED Seek FDA Approval for Orpathys-Tagrisso Lung Cancer Combo
AstraZeneca and HUTCHMED have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Orpathys (savolitinib) in combination...
AstraZeneca Secures FDA Priority Review for Imfinzi Bladder Cancer Combo
AstraZeneca said the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to its supplemental Biologics License Application for Imfinzi...
AstraZeneca's Rare Disease Drug Efzimfotase Alfa Granted FDA Priority Review
AstraZeneca's rare disease unit, Alexion, announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for...
AstraZeneca's Enhertu Nears EU Approval, Cuts Breast Cancer Risk by 53%
A European Medicines Agency panel recommended the approval of Enhertu, a cancer drug from AstraZeneca and Daiichi Sankyo. The positive opinion from the...
AstraZeneca Gains as NHS Approves Enhertu, Plans New China Hub
AstraZeneca shares rose on September 17, 2026, following two major strategic milestones. England’s National Health Service (NHS) approved the breast cancer...
AstraZeneca Shares Slide, Breast Cancer Drug Etcamah Fails Late-Stage Trial
AstraZeneca shares fell on September 11 following disappointing clinical results. The company’s breast cancer drug, Etcamah (camizestrant), failed to meet its...
🔴 AstraZeneca is trading 3.23% down in after-hours trading amid reported $15 billion ivonescimab licensing talks
AstraZeneca is trading 3.23% down at $154.99 after reports that it is negotiating a potential licensing deal with Summit Therapeutics for ivonescimab,...
AstraZeneca tozorakimab cuts COPD flare-ups by 30%, targeting broader patient group
AstraZeneca announced full results from its OBERON and TITANIA Phase 3 trials for tozorakimab. The experimental drug reduced moderate-to-severe COPD flare-ups...
AstraZeneca Wins FDA Approval for Etcamah, Cutting Cancer Progression Risk 56%
The FDA granted accelerated approval to AstraZeneca’s Etcamah (camizestrant) for adults with HR-positive, HER2-negative advanced breast cancer. This approval...
AstraZeneca, Daiichi Sankyo win EU approval for Enhertu, first regimen in decade
The European Commission approved AstraZeneca and Daiichi Sankyo’s Enhertu, combined with pertuzumab, for first-line treatment of unresectable or metastatic...
AstraZeneca hits Phase III goals for Tagrisso combo, boosting lung cancer survival
AstraZeneca and HUTCHMED reported positive results from the SANOVO Phase III trial in China. The study evaluated Tagrisso (osimertinib) combined with Orpathys...
AstraZeneca secures $1.5B rights for Zegfrovy, targeting rare lung cancer mutations
AstraZeneca finalized an exclusive global licensing agreement with Dizal Pharmaceutical for the lung cancer drug Zegfrovy. The deal grants AstraZeneca...